A new therapy for ovarian cancer has been developed by AstraZeneca, it has been announced.
The drug, Lynparza, has received a European regulatory recommendation, after showing promising results for ovarian cancer.
It has been endorsed for approval as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive, relapsed, BRCA-mutated ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy.
Based on its proven positive safety and efficacy data from a phase II clinical trial, Lynparza has been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to the European Commission to grant the drug its final approval.
If successful, the drug could become the first PARP inhibitor to be made available in Europe for the treatment of this serious form of ovarian cancer.
Executive Vice-President for Global Medicines Development and Chief Medical Officer at AstraZeneca, Briggs Morrison, said, “We are committed to investigating the full potential of olaparib and have a number of studies underway in multiple tumour types including breast and gastric cancer.”
This follows the publication of positive results from a phase IIb study of the company’s new severe asthma therapy benralizumab earlier this month.